<DOC>
	<DOCNO>NCT01980615</DOCNO>
	<brief_summary>This Phase I , Randomized , Double-Blind Within Device , Single-Dose , Four-Period , Six-Treatment , Cross-Over Study Evaluating Safety Pharmacokinetics Three Doses Budesonide , Glycopyrronium , Formoterol Fumarate Inhalation Aerosol ( BGF MDI ) , One Dose Glycopyrronium Formoterol Fumarate Inhalation Aerosol ( GFF MDI ) , Two Doses SymbicortÂ® Inhalation Aerosol Healthy Volunteers . The primary objective study determine dose budesonide formulate glycopyrronium formoterol fumarate BGF MDI provide comparable systemic exposure [ pharmacokinetics ( PK ) ] budesonide follow administration Symbicort MDI .</brief_summary>
	<brief_title>Phase I Study Evaluating Safety Pharmacokinetics Budesonide , Glycopyrronium , Formoterol Fumarate Inhalation Aerosol ( BGF MDI ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Provide sign write informed consent form 18 45 year ( inclusive ) Healthy subject confirm thorough medical history physical examination , ECG , vital sign clinical laboratory test Females childbearing potential male female partner childbearing potential must agree use medically acceptable contraception Body mass index ( BMI ) 18.5 32 kg/m2 ( inclusive ) minimum weight 50 kg screen visit Results complete laboratory analysis within normal range determine clinically significant Investigator Pregnancy , nurse female subject , subject try conceive Clinically significant medical condition History ECG abnormalities Symptomatic prostatic hypertrophy , bladder neck obstruction , urinary retention Known diagnosis glaucoma Known suspect history substancerelated disorder within 1 year screen Treatment investigational drug within 30 day five halflives ( whichever longer ) prior screen period Hypersensitivity lactose drug component formulation ( ) use study Positive screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) positive hepatitis C antibody screen . Major surgery within four week minor surgery within 2 week drug administration Any condition and/or situation cause Investigator deem subject unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>